Q32 Bio Inc. (QTTB)
QTTBNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$9.20
+0.0100 (+0.11%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $9.37 +1.87%
- Market cap
- $275.30m
- P/E
- 3.8
- EPS, last 4 quarters
- $2.41
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.91 to $23.57
- Average volume
- –
- Previous close
- $9.19
Analysts
8 coveringBuy7 buy, 1 hold, 0 sell
Targets a year out average $39.43, +328.6% from here
Earnings
next estimate $-0.3000Next report
Dec 2025
+529.4%
Mar 2026
-3.9%
Jun 2026
+17.0%
Sep 2026
+27.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $53.74m | – | – | – |
| Gross profit | $53.74m | – | – | – |
| Operating income | $45.88m | -$7.72m | -$9.12m | -$10.66m |
| Net income | $57.73m | -$7.61m | -$8.95m | -$8.92m |
News
8 latest- Q32 Bio Reports Q3 Results; Advances Bempikibart Toward Phase 3 In Alopecia Areata RTTNews · Nov 4, 2026
- Leerink Partners Initiates Coverage of Q32 Bio with OutperformFintel · Oct 12, 2026
- Q32 Bio Sets 2027 Registration Program For Bempikibart In Alopecia RTTNews · Sep 30, 2026
- Q32 Bio Reports Bempikibart Data In Alopecia Areata RTTNews · Sep 30, 2026
- Jefferies Initiates Coverage of Q32 Bio with BuyFintel · Sep 28, 2026
- Q32 Bio Appoints New CMO And CDO To Support Advancement Of Bempikibart RTTNews · Sep 14, 2026
- Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround Zacks · Sep 7, 2026
- Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?Zacks · Aug 17, 2026
The company
Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7R antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- q32bio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.